ANVS Annovis Bio Inc.

25.76
-0.1  0%
Previous Close 25.86
Open 25
52 Week Low 5.25
52 Week High 132
Market Cap $208,670,683
Shares 8,100,570
Float 5,639,681
Enterprise Value $209,978,689
Volume 46,480
Av. Daily Volume 239,962
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
ANVS401
Alzheimer’s disease (AD) and Parkinson’s disease (PD)
Phase 2a
Phase 2a
Phase 2a data showed improvements in cognition in AD patients by 4.4 points compared to placebo at 3.3. WAIS coding in AD patients show a statistically-significant 23% improvement and PD patients a statistically-significant 24% improvement compared with placebo, noted September 2021. Phase 2a of PD patients noted statistically significant improvements in WAIS coding scores, in the UPDRS 2, 3, 4, and in total MDS-UPDRS test compared to baseline, noted October 5, 2021. Additional Phase 2a data reported reduced neurotoxic proteins in both AD and PD patients, with decreased inflammation and improved axonal integrity and synaptic functions in both AD and PD patients, noted November 12, 2021. Phase 3 trials to be initiated 1Q 2022.

Latest News

    • Richard Fitzgerald Joins as Chief Financial Officer
    • John Franzino Transitions to Chief Administrative Officer

    BUFFALO, N.Y., Nov. 19, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, announced today that Richard Fitzgerald has joined the Company as its Chief Financial Officer, effective November 15, 2021. John Franzino, the Company's previous Chief Financial Officer, has transitioned to Chief Administrative Officer, where he will be responsible for further developing the company's business processes and leading the Company's financial planning and analysis…

    • Richard Fitzgerald Joins as Chief Financial Officer

    • John Franzino Transitions to Chief Administrative Officer

    BUFFALO, N.Y., Nov. 19, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, announced today that Richard Fitzgerald has joined the Company as its Chief Financial Officer, effective November 15, 2021. John Franzino, the Company's previous Chief Financial Officer, has transitioned to Chief Administrative Officer, where he will be responsible for further developing the company's business processes and leading the Company's financial planning and analysis, operational finance, human resources, and information technology functions.

    "This is a pivotal time for 22nd Century as we build out our leadership team, particularly with the pending MRTP authorization and international launch of our VLN® product," said James A. Mish, chief executive officer at 22nd Century Group. "We are excited to welcome Rich to the team, expanding our financial and strategic capabilities as we work to rapidly scale the business across all three of our plant franchises. Rich brings a diverse background, including extensive experience in IP and technology licensing in the life science industry, which we believe is timely as we execute on our key launch programs in tobacco, hemp/cannabis and hops."

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/08064608-6248-4a24-b66c-98b1a9ad88ac

    "John has been an important part of 22nd Century's transformation since joining the Company. He has helped the Company advance our primary mission in tobacco harm reduction and to take leadership positions in two new plant franchises, enabling us to expand our revenue base, diversify into international markets, and build our balance sheet to its strongest level in Company history. In his role as Chief Administrative Officer, John will focus on further developing our corporate and operational capabilities to support our growth as we bring VLN® to market, begin to monetize our hemp/cannabis portfolio and expand our global operations across all three franchises," said Mish.

    "I am excited to join 22nd Century as the Company readies for a significant change in its revenue model through the launch of its disruptive VLN® product and monetization of its highly differentiated hemp/cannabis portfolio through both IP and plant line revenues," said Fitzgerald. "22nd Century has positioned itself as a critical industry partner across all three of its franchises, and I look forward to building on this foundation as we continue to scale the company."

    Fitzgerald's other roles include serving as Chief Financial Officer and Secretary of CleanTech Acquisition Corp, (NASDAQ:CLAQU), a SPAC focused on the CleanTech sector. Previously, he was a consulting CFO for Atrin Pharmaceuticals, a novel DNA Damage Repair focused oncology platform, Co-Founder and CFO of SIRPant Immunotherapeutics and CFO of Immunome (NASDAQ:IMNM), where he helped lead the company's initial public offering onto the Nasdaq. Additionally, Fitzgerald has held financial executive roles at Sesen Bio (NASDAQ:SESN), Annovis Bio (NYSE:ANVS), and Pavmed (NASDAQ:PAVM), among others. He began his career as a Senior Manager in audit and transactions services at Coopers & Lybrand LLP, now PricewaterhouseCoopers. He holds a B.S., Business Administration, Accounting from Bucknell University.

    About 22nd Century Group, Inc.

    22nd Century Group, Inc. (Nasdaq: XXII) is a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the Company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of the FDA's Comprehensive Plan to address the widespread death and disease caused by smoking. In tobacco, hemp/cannabis, and hop plants, 22nd Century uses modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new, proprietary plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits.

    Learn more at xxiicentury.com, on Twitter @_xxiicentury, and on LinkedIn.

    Cautionary Note Regarding Forward-Looking Statements

    Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements typically contain terms such as "anticipate," "believe," "consider," "continue," "could," "estimate," "expect," "explore," "foresee," "goal," "guidance," "intend," "likely," "may," "plan," "potential," "predict," "preliminary," "probable," "project," "promising," "seek," "should," "will," "would," and similar expressions. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in "Risk Factors" in the Company's Annual Report on Form 10-K filed on March 11, 2021. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

    Investor Relations & Media Contact:

    Mei Kuo

    Director, Communications & Investor Relations

    22nd Century Group, Inc.

    (716) 300-1221

     



    Primary Logo

    View Full Article Hide Full Article
  1. Trading to begin November 18, 2021 with current ticker "ANVS"

    Berwyn, Pennsylvania--(Newsfile Corp. - November 15, 2021) - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative diseases, today announced that the New York Stock Exchange ("NYSE") has approved the transfer of the listing of its common stock from the NYSE American LLC ("NYSE American") to the NYSE. The Company's common stock will begin trading under the symbol "ANVS" at the opening of trading on November 18, 2021.

    Annovis' Founder, President and CEO of Annovis Maria Maccecchini, Ph.D., commented: "I am pleased to announce our transfer to the NYSE…

    Trading to begin November 18, 2021 with current ticker "ANVS"

    Berwyn, Pennsylvania--(Newsfile Corp. - November 15, 2021) - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative diseases, today announced that the New York Stock Exchange ("NYSE") has approved the transfer of the listing of its common stock from the NYSE American LLC ("NYSE American") to the NYSE. The Company's common stock will begin trading under the symbol "ANVS" at the opening of trading on November 18, 2021.

    Annovis' Founder, President and CEO of Annovis Maria Maccecchini, Ph.D., commented: "I am pleased to announce our transfer to the NYSE, a major financial milestone for the entire Company. We are now better positioned to improve stock liquidity and attract a broader pool of investors. We believe this will enhance the value of our Company as we advance our lead compound ANVS401 towards the next steps of its clinical evaluation in AD and PD patients."

    About Annovis Bio, Inc.

    Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD), and Alzheimer's in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD, and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We conducted two Phase 2 studies: one in AD patients and one in both AD and PD patients. In the AD/ PD study our drug improves memory loss and dementia associated with AD, as well as body and brain function in PD.

    For more information on Annovis Bio, please visit the company's website www.annovisbio.com and follow us on LinkedIn and Twitter.

    Forward-Looking Statements

    Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words, and include, without limitation, statements regarding the timing, effectiveness, and anticipated results of ANVS401 clinical trials. Forward-looking statements are based on Annovis Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.

    ###

    Media and Investor Contact:
    Nic Johnson
    Russo Partners, LLC
    (303) 482-6405

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/103528

    View Full Article Hide Full Article
  2. With additional data, the primary, secondary, and exploratory endpoints were met in Phase 2a study

    Berwyn, Pennsylvania--(Newsfile Corp. - November 12, 2021) - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative diseases, today reported new data on ANVS401 from the Company's Phase 2a study during the 14th Clinical Trials on Alzheimer's Disease conference (CTAD).

    ANVS401 is an oral translational inhibitor of neurotoxic aggregating proteins (TINAPs) currently being developed for AD, AD in Down Syndrome, and PD. In the Phase 2a trial, ANVS401 was shown to be well-tolerated and safe, and its pharmacokinetics was…

    With additional data, the primary, secondary, and exploratory endpoints were met in Phase 2a study

    Berwyn, Pennsylvania--(Newsfile Corp. - November 12, 2021) - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative diseases, today reported new data on ANVS401 from the Company's Phase 2a study during the 14th Clinical Trials on Alzheimer's Disease conference (CTAD).

    ANVS401 is an oral translational inhibitor of neurotoxic aggregating proteins (TINAPs) currently being developed for AD, AD in Down Syndrome, and PD. In the Phase 2a trial, ANVS401 was shown to be well-tolerated and safe, and its pharmacokinetics was found to be in line with levels measured earlier in humans, meeting both the primary and secondary endpoints. Additionally, exploratory endpoints were met when the Phase 2a data showed that ANVS401 treatment resulted in statistically significant improvement in motor function in PD patients and cognition in AD patients.

    Data from the Phase 2a clinical trial presented today at CTAD showed that treatment with ANVS401 reduced neurotoxic proteins in both AD and PD patients (Figure 1). Further, ANVS401 decreased inflammation and improved axonal integrity and synaptic functions in both AD and PD patients (Figure 2 and Figure 3). All values are in comparison to placebo and are based on all data points.

    Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7656/103254_ddbba3fb040e389b_002.jpg

    Figure 1 - APP (and its downstream products), t-Tau, and p-Tau are the neurotoxic proteins involved in AD, while α-Synuclein (α-Syn) is the neurotoxic culprit of PD.

    To view an enhanced version of Figure 1, please visit:
    https://orders.newsfilecorp.com/files/7656/103254_ddbba3fb040e389b_002full.jpg.

    Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7656/103254_ddbba3fb040e389b_003.jpg

    Figure 2 - Inflammatory markers are lowered in both AD and PD patients, showing a stabilization of inflammation in both neurodegenerative disorders.

    To view an enhanced version of Figure 2, please visit:
    https://orders.newsfilecorp.com/files/7656/103254_ddbba3fb040e389b_003full.jpg.

    Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7656/103254_ddbba3fb040e389b_004.jpg

    Figure 3 - Neuronal and synaptic markers are lowered in both AD and PD patients, meaning that the nerve cells are healthier.

    To view an enhanced version of Figure 3, please visit:
    https://orders.newsfilecorp.com/files/7656/103254_ddbba3fb040e389b_004full.jpg.

    This data strengthens the understanding of optimal ANVS401-induced neurotoxic protein reduction in both animal models and humans. In the Phase 2a study, most biomarkers and inflammatory markers of both AD and PD treated patients were reduced by 3 to 20% at ANVS401 doses that saw significant improvement in cognition and function. This aligns with AD and PD mouse model studies that showed APP and α-Syn were reduced by 5 to 20% and 3 to 10%, respectively, at ANVS401 doses that also saw significant improvement in cognition and function. This suggests that slight changes in ANVS401-reduced neurotoxic proteins result in significant downstream effects in both animals and humans.

    "We believe we have begun to unravel the relationship between biomarker reduction and efficacy, a topic that has been a focus of research for some time. By comparing biomarker levels at fully effective doses of ANVS401 in both mice and humans suffering from AD and PD, we see that a small reduction in biomarkers and inflammatory markers is sufficient to lead to statistically significant improvements in outcomes," commented Founder, President and CEO of Annovis Maria Maccecchini, Ph.D. "Meeting primary endpoints and the reversal of the toxic cascade combined with improvements in cognition and function are the foundation for us to ask the FDA for two meetings - one to move into two phase 3 clinical trials for AD and one to move into two phase 3 clinical trials for PD."

    The primary endpoint of the Phase 2a clinical trials, safety, was met as no serious adverse events (AEs) and no AEs leading to dosage withdrawal were observed in both Phase 2a clinical trials. It should be noted that most AEs were due to spinal fluid collection, which typically results in headaches and back aches in patients. Another endpoint was pharmacokinetics and the plasma levels of ANVS401 measured in this study corresponded to plasma levels seen in previous human studies.

    A replay of the presentation will be available on demand on the conference website after 48 hours. The presentation slides will be also available on the Investors & Media tab of the Annovis website.

    About Annovis Bio, Inc.
    Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD), and Alzheimer's in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD, and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We conducted two Phase 2 studies: one in AD patients and one in both AD and PD patients. In the AD/ PD study our drug improves memory loss and dementia associated with AD, as well as body and brain function in PD.

    For more information on Annovis Bio, please visit the company's website www.annovisbio.com and follow us on LinkedIn and Twitter.

    Forward-Looking Statements
    Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words, and include, without limitation, statements regarding the timing, effectiveness, and anticipated results of ANVS401 clinical trials. Forward-looking statements are based on Annovis Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.

    ###

    Media and Investor Contact:
    Nic Johnson
    Russo Partners, LLC
    (303) 482-6405

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/103254

    View Full Article Hide Full Article
  3. Poster highlighting the mechanism of action for ANVS401 is on display onsite and online

    Berwyn, Pennsylvania--(Newsfile Corp. - November 9, 2021) - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative diseases, today announced that Vice President of Research, Cheng Fang, Ph.D. will present the ANVS401 mechanism of action via a poster presentation, on display both onsite and online, during the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference.

    The poster presentation, titled "Translational inhibition of neurotoxic aggregating proteins leads to efficacy in Alzheimer's and Parkinson's patients*," can…

    Poster highlighting the mechanism of action for ANVS401 is on display onsite and online

    Berwyn, Pennsylvania--(Newsfile Corp. - November 9, 2021) - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative diseases, today announced that Vice President of Research, Cheng Fang, Ph.D. will present the ANVS401 mechanism of action via a poster presentation, on display both onsite and online, during the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference.

    The poster presentation, titled "Translational inhibition of neurotoxic aggregating proteins leads to efficacy in Alzheimer's and Parkinson's patients*," can be viewed in person in the Statler Room of the Boston Park Plaza Hotel, Boston, MA during lunch and coffee breaks. The digital version of the poster is now available on the CTAD digital platform to registered conference attendees. All abstracts will also be published in the Journal of Prevention of Alzheimer's Disease (JPAD).

    Annovis' lead compound, ANVS401, is an oral translational inhibitor of neurotoxic aggregating proteins (TINAP) currently being developed for AD, AD in Down Syndrome (AD-DS), and PD. The mRNAs of neurotoxic aggregating proteins, including Amyloid-beta precursor protein (APP), t-Tau and p-Tau, as well as α-Synuclein (α-Syn), have a unique sequence which regulates translation of these proteins. ANVS401 acts on that sequence to inhibit the translation of neurotoxic proteins. By preventing the overexpression of these neurotoxic proteins, ANVS401 reverses the downstream toxic cascade that leads to neurodegeneration. Slight reductions in neurotoxic proteins at the beginning of the toxic cascade have been shown in the Company's animal studies and Phase 2a clinical trials in AD and PD to reinstate homeostasis and to lead to statistically significant improvements in cognition in AD patients and motor function in PD patients.

    *The poster appears with the title "Positive clinical outcomes of posiphen in two phase2a studies - Alzheimer' disease and Parkinson's disease" on the conference program due to a copy error.

    About Annovis Bio, Inc.

    Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD), and Alzheimer's in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD, and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We conducted two Phase 2 studies: one in AD patients and one in both AD and PD patients. In the AD/ PD study our drug improves memory loss and dementia associated with AD, as well as body and brain function in PD.

    For more information on Annovis Bio, please visit the company's website www.annovisbio.com and follow us on LinkedIn and Twitter.

    Forward-Looking Statements

    Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words, and include, without limitation, statements regarding the timing, effectiveness, and anticipated results of ANVS401 clinical trials. Forward-looking statements are based on Annovis Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.

    ###

    Media and Investor Contact:
    Nic Johnson
    Russo Partners, LLC
    (303) 482-6405

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/102523

    View Full Article Hide Full Article
  4. Dr. Maria Maccecchini will present additional Phase 2 data on November 12, 10:25 a.m. EST

    A poster highlighting the mechanism of action for ANVS401 will be on display onsite and online

    Berwyn, Pennsylvania--(Newsfile Corp. - November 2, 2021) - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative diseases, today announced that the Company's representatives will give both an oral and poster presentation at the 14th Clinical Trials on Alzheimer's Disease conference (CTAD) hosted in-person and virtually at the Boston Park Plaza, Boston, MA from November 9-12, 2021.

    The poster presentation will highlight the mechanism…

    Dr. Maria Maccecchini will present additional Phase 2 data on November 12, 10:25 a.m. EST

    A poster highlighting the mechanism of action for ANVS401 will be on display onsite and online

    Berwyn, Pennsylvania--(Newsfile Corp. - November 2, 2021) - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative diseases, today announced that the Company's representatives will give both an oral and poster presentation at the 14th Clinical Trials on Alzheimer's Disease conference (CTAD) hosted in-person and virtually at the Boston Park Plaza, Boston, MA from November 9-12, 2021.

    The poster presentation will highlight the mechanism of action of ANVS401, a small lipophilic molecule which disrupts translation of neurotoxic proteins via the iron homeostatic process. The oral presentation will elaborate on new biomarker data from the initial Phase 2 clinical trial, as well as expanded safety information from the full range of study participants. All abstracts will be published in the Journal of Prevention of Alzheimer's Disease (JPAD).

    Poster Details:
    Title: Translational inhibition of neurotoxic aggregating proteins leads to efficacy in Alzheimer's and Parkinson's patients*
    Poster ID: LP13
    Time: Available digitally Tuesday, November 9, 8 a.m. EST; in-person during coffee breaks and lunches
    Presenter: Cheng Fang, Ph.D., Vice President of Research, Annovis Bio

    Oral Presentation Details:
    Title: Positive clinical outcomes of posiphen in two phase 2a studies - Alzheimer's disease and Parkinson's disease
    Presentation ID: LB14
    Time: Friday, November 12, 10:25 a.m. EST; in-person and livestreamed
    Presenter: Maria Maccecchini, Ph.D., Founder, CEO and President, Annovis Bio

    *Due to a misprint, the poster appears with the title "Positive clinical outcomes of posiphen in two phase2a studies - Alzheimer' disease and Parkinson's disease" on the conference program.

    About Annovis Bio, Inc.

    Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD), and Alzheimer's in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD, and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We conducted two Phase 2 studies: one in AD patients and one in both AD and PD patients. In the AD/ PD study our drug improves memory loss and dementia associated with AD, as well as body and brain function in PD.

    For more information on Annovis Bio, please visit the company's website www.annovisbio.com and follow us on LinkedIn and Twitter.

    Forward-Looking Statements

    Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words, and include, without limitation, statements regarding the timing, effectiveness, and anticipated results of ANVS401 clinical trials. Forward-looking statements are based on Annovis Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.

    ###

    Media and Investor Contact:
    Nic Johnson
    Russo Partners, LLC
    (303) 482-6405

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/101625

    View Full Article Hide Full Article
View All Annovis Bio Inc. News